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An 83-year-old man underwent computed tomography during a routine check-up due to a history of surgical
treatment for pancreatic cancer. Two tumors were detected in the anterior segment of the liver. A needle biopsy of
the larger tumor was performed, and pathological examination showed that the tumor was a poorly differentiated
hepatocellular carcinoma. Resection was not performed considering the patient’s poor physical condition. Thus,
transcatheter arterial chemoembolization and radiofrequency ablation of the tumors were performed. Three months
later, residual tumor of the larger lesion and multiple pulmonary metastases were detected. This time, continuous
hepatic arterial infusion chemotherapy was performed. Although the pulmonary metastases markedly reduced, tumor
thrombi appeared in the right portal vein on computed tomography. Finally, sorafenib was administered, which led
to disappearance of the tumor thrombi and no other signs of recurrence 8 months after initiation of sorafenib on
computed tomography. Although sorafenib administration has continued at reduced doses of 200 mg per day or less
due to hypertension, complete response has persisted for the past 34 months. It is noteworthy that sorafenib has been
given at reduced doses, but a long-term complete response is maintained in a patient who had portal tumor thrombi
and distant metastasis. Herein, we present this rare case of advanced hepatocellular carcinoma controlled with reduced
doses of sorafenib following multidisciplinary therapy, describe our single center experience with sorafenib use in
patients with hepatocellular carcinoma, and review previous reports that focused on dose reduction of sorafenib.
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Although potentially curative therapies including liver
transplantation, resection, and ablations have been devel-
oped for hepatocellular carcinoma (HCC), patients with
advanced stage of HCC still have poor prognosis [1-3].
The recent development of molecular targeted therapies
has begun to change strategies for treating advanced* Correspondence: itano@z8.keio.jp
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unless otherwise stated.HCC. The efficacy and safety of sorafenib for advanced
HCC were assessed in the SHARP study [4] and also in
the Asia-Pacific study [5]. To date, sorafenib has been
applied to a large number of patients worldwide and be-
comes an important therapeutic option for HCC. A grow-
ing number of complete response (CR) patients have been
reported since 2008 [6]. Recently, a Japanese multi-center
study has reported 18 patients with HCC who achieved
CR after sorafenib treatment and precisely described their
characteristics [7]. However, it is still very difficult and ex-
tremely rare to maintain CR for long term in patients withl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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HCC that was initially treated with multidisciplinary ther-
apy and has maintained a CR status for 34 months using
reduced doses of sorafenib. We also describe our single-
center experience for sorafenib use in patients with HCC
and review previous reports that focused on HCC patients
with long-term CR using reduced doses of sorafenib.
Case presentation
An 83-year-old Japanese man underwent distal pancrea-
tectomy for pancreatic body cancer 3 years ago. He had
a medical history of hypertension but not of hepatitis
virus infection and alcohol abuse. During a postoperative
surveillance examination, contrast-enhanced computedA) 
B) 
Figure 1 Gadoxetic acid-enhanced magnetic resonance imaging
at tumor discovery. Images in the arterial-phase are shown. (A) A
large tumor, 23 mm in diameter, is adjacent to the right Glisson
branch (white arrow). The dorsal side of the tumor is hypervascular
(early enhancement is indicated by white triangles), and the ventral
side is hypovascular (indicated by a black triangle). (B) A smaller
tumor, 13 mm in diameter, is below the right diaphragm. The tumor
also shows early enhancement (indicated by a white triangle).tomography (CT) detected two tumors, 23 and 13 mm
in diameter, in the anterior segment of the liver. The larger
tumor was adjacent to the right main Glisson branch, and
the other lesion was below the right diaphragm. Both of
them showed early enhancement in the arterial phase
(Figure 1A,B) and hypointensity in the hepatobiliary phase
in the gadoxetic acid-enhanced magnetic resonance im-
aging. The patient’s serum alpha-fetoprotein (AFP) level
was elevated to 8,650 ng/ml (normal level is less than
20 ng/ml). A needle biopsy of the larger tumor was per-
formed, and pathological examination showed that the
tumor was a poorly differentiated hepatocellular carcin-






Figure 2 Abdominal contrast-enhanced computed tomography
before and after sorafenib introduction. (A) Before sorafenib
introduction. Massive filling defects with enhancement are seen in
the anterior and posterior branches of the portal vein (indicated
by white triangles). An artifact by the catheter and coil placed for
hepatic arterial infusion chemotherapy is seen. (B) After sorafenib
introduction. The tumor thrombi disappeared in the portal vein
(indicated by white triangles). Ant. PV, anterior branch of the portal
vein; Post. PV, posterior branch of the portal vein.
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carcinoma was identical to the one diagnosed at the time
of surgery; and components of hepatoid carcinoma were
not found in this specimen. Resection was not performed
considering the tumor location (right lobectomy was ne-
cessary) and the patient’s hepatic functional reserve (Child-
Pugh classification was grade A, but indocyanine green
retention rate at 15 min was 21%) and advanced age.
Since the larger tumor was adjacent to the right main
Glisson branch and only the bordering side appeared
hypervascular, we first performed transcatheter arterial
chemoembolization to the hypervascular part of the lar-
ger tumor and to the other tumor and then additionally
performed radiofrequency ablation of the hypovascular
portion of the larger tumor. Three months after the
treatment, CT imaging revealed a residual tumor of the
larger lesion at the ablation site and multiple lung
metastases. Thus, continuous hepatic arterial infusion
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Figure 3 Clinical course as assessed by tumor markers and therapeut
HCC, hepatocellular carcinoma; TACE, transcatheter arterial chemoemboliza
chemotherapy; AFP, alpha-fetoprotein.performed for 2 months. This was effective in reducing
the residual tumor and lung metastases, but tumor
thrombi appeared in the right portal vein (Figure 2A),
and his AFP and PIVKA-II levels were elevated to
41,948 ng/ml and 422 mAU/mL, respectively (Figure 3).
Subsequently, sorafenib was administered at a reduced
dose of 400 mg per day considering his advanced age
(the manufacturer’s recommended dose is 800 mg per
day). The dose of sorafenib was temporarily increased to
800 mg per day but was reduced to 400 mg per day
again due to an adverse event of hypertension (grade 3
in Common Terminology Criteria for Adverse Effects
version 4.0) (doses are described in Figure 3). Eight
months after initiation of sorafenib, his AFP level was
decreased to normal level, and both the tumor thrombi
in the right portal vein and multiple lung metastases
disappeared on CT imaging (Figure 2B). The dose of
sorafenib was further reduced to 200 mg per day or
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tion; RFA, radiofrequency ablation; HAIC, hepatic arterial infusion
Table 1 Cases who achieved complete response for more than 2 years in the literature
Case 1 Case 2 Case 3 Case 4 Present case
Reported year [reference] 2011 [8] 2011 [8] 2013 [9] 2013 [10] 2014
Age/sex 70/male 69/male 71/male 74/male 83/male
Background liver disease Hepatitis C Hepatitis C Hepatitis C Hepatitis B Non-viral, non-alcoholic
Tumor status at sorafenib
initiation
Number Single Not described Multiple Single -
Location Not described Three hepatic lesions Segment IV and VII Posterior segment Right lobe
Maximum size 6 × 5 cm Not described 9 cm 8.6 × 5.7 cm -
Extension Vascular invasion Portal vein thrombosis Portal vein thrombosis Vertebral metastasis Lung metastasis
Pathological diagnosis None (based on the computed
tomography image)










None Not described Synchro-level, Vitamin E TACE→ PEIT, RFA TACE + RFA→ HAIC (5-FU + CDDP)
Doses of sorafenib (period)
Initial dose Not described 800 mg/day (10 days) 800 mg/day (2 months) 800 mg/day (2 weeks) 400 mg/day (1 month)
Second dose → 400 mg/day (55 months) → 400 mg/day (3 months) → 400 mg/day (18 months) → 400 mg/day
(60 months)
→ 200 mg/day (1 months)
Third dose → 400 mg/2 days (57 months) → 800 mg/day (4 months)
Fourth dose → 400 mg/day (2 months)
Last doses → 200→ 100→ 200 mg/day (34 months)
Total period of sorafenib 60 months 62 months 20 months 60 months 42 months
Period of complete
response
<27 months 38 months 28 months 54 months 34 months
Reported status Alive Alive Alive Alive Alive
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AFP and PIVKA-II levels have also been within the nor-
mal limits for the past 34 months.
Discussion
This patient underwent multidisciplinary therapy includ-
ing transcatheter arterial chemoembolization, radiofre-
quency ablation, and continuous hepatic arterial infusion
chemotherapy until tumor thrombi were found in the
portal vein. We finally initiated sorafenib treatment, and
the patient achieved CR soon afterwards and has main-
tained the CR status for the past 34 months. Based on
the clinical course of this patient, the achievement of CR
was predominantly attributed to sorafenib therapy. It is
extremely rare that a patient with advanced HCC and
portal tumor thrombi can achieve long-term CR without
resection.
According to the published literature, there were only
four cases of HCC who achieved CR using mainly soraf-
enib and maintained the status for more than 2 years
[8-10]. Table 1 summarizes the patient characteristics of
the four reported cases and the present case. All patients
were male, and the mean age was 73.4 years old. The0  6  12  18  
800mg/day 600mg/day
Months after sora
Case 1: 76F 
Case 2: 85M 
Case 3: 61M
Case 4: 84M 
Case 5: 80M 
Case 6: 74F 
Case 7: 65F 

























Figure 4 List of cases treated with sorafenib for hepatocellular carcin
shown in descending order of length of sorafenib treatment. Case 2 repres
sorafenib initiation.background liver disease was hepatitis C in three cases,
hepatitis B in one case, and nothing in one case (present
case). The extent of HCC was major vascular invasion in
three cases, distant metastasis in one case, and both major
vascular invasion and distant metastasis in one case
(present case). It is noteworthy that sorafenib was initiated
at the recommended dose (800 mg per day) in three cases,
but the dose was soon reduced to 400 mg per day or less
in all of them. The final maintenance dose of sorafenib
was 400 mg per day in the four reported cases and
200 mg per day in the present case, although the SHARP
[4] and Asia-Pacific [5] studies reported that efficacy of so-
rafenib for advanced HCC was maximally observed at the
dose of 800 mg per day.
We also surveyed our single department with regard
to sorafenib use for advanced HCC. In 2010, sorafenib
became commercially available for advanced HCC in
Japan and has been administered to 32 patients with ad-
vanced HCC so far in our department. We applied sorafe-
nib at the recommended dose of 800 mg per day in seven
patients (cases 1, 6, 20, 27, 29, 31, and 32 in Figure 4), but
all of the patients did not tolerate this recommended dose
due to side effects or disease progression. Thus, the dose24  30  36  42  48  
400mg/day 200mg/day 200mg/alt.day
fenib initiation
oma in our department and the doses of sorafenib. Cases are
ents the present case. Ages shown are at the time of
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and the treatment itself was discontinued in five cases
(cases 20, 27, 29, 31, and 32 in Figure 4) within 3 months
after initiation of sorafenib. We also found that 14 cases
(cases 1 to 14 in Figure 4) took sorafenib for more than
12 months and 7 cases (cases 1 to 7 in Figure 4) took so-
rafenib for more than 18 months. Most of the long-term
recipients of sorafenib were not given the recommended
dose of 800 mg per day and had instead reduced doses for
most of the treatment period.
Conclusion
We present here a rare case of advanced HCC, who was
initially treated with multidisciplinary therapy including
transcatheter arterial chemoembolization, radiofrequency
ablation, and continuous hepatic arterial infusion chemo-
therapy, and achieved long-term CR using reduced doses
of sorafenib. Based on our single-center experience of so-
rafenib use in patients with HCC and the previously re-
ported cases of long-term CR using sorafenib, it appears
that it is important to continue sorafenib for a long time
even if the dose is reduced. We hope that this case presen-
tation and literature review serves as a stimulus for further
investigation to clarify if using reduced doses of sorafenib
for maintenance increase the incidence of CR.
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